Two prominent European biospecimen and life sciences companies have combined to strengthen research capabilities across Europe and North America, marking significant expansion in biospecimen services and stem cell research sectors.
A new automated screening technology developed by Japanese researchers enables rapid identification of drug candidates by tracking molecular behaviour within cells, offering significant implications for therapeutic development.
Finnish researchers have developed a high-throughput screening pipeline that enables simultaneous analysis of multiple drug responses in primary tumour samples at single-cell resolution, offering new possibilities for personalised cancer therapy.
Researchers at the University of Bonn have developed an artificial intelligence system that can predict chemical structures of compounds capable of binding to multiple protein targets, potentially streamlining the discovery of more effective therapeutic agents.
Researchers at Linköping University have developed an improved version of the AI protein structure prediction tool AlphaFold, enabling analysis of larger protein complexes and integration of experimental data. The advancement marks a significant step forward in protein research and drug development.
New biosafety level 2 laboratories to support enzyme development
Biotech firms VALANX Biotech and Fina Biosolutions have announced a collaborative agreement to commercialise ClickCRM, an engineered version of the carrier protein CRM197 designed to accelerate conjugate vaccine development. The partnership, announced on 29 October 2024, combines VALANX’s expertise in site-specific protein conjugation with FinaBio’s established presence in conjugate vaccine development.
At this year’s Human Proteome Organization (HUPO) World Congress in Dresden, proteomics specialist Biognosys unveiled significant developments in protein analysis technology, with particular emphasis on their novel P2 Plasma Enrichment System.
Takara Bio Europe has expanded its Gothenburg facility with a new custom manufacturing laboratory, significantly boosting its capacity to produce molecular biology reagents for the EMEA region. The facility, which became operational on 1 October 2024, is capable of manufacturing up to 600,000 reactions weekly, addressing the growing demands of academic research institutions, diagnostic laboratories, […]
Partnership focuses on Cue system integration
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
